The current status of neural grafting in the treatment of Huntington's disease. a review

Frontiers in Integrative Neuroscience

Volumn , Issue DECEMBER, 2011, Pages

  Wijeyekoon, Ruwani ^a   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Clinical studies; Huntington's disease; Neural transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; DOPAMINE 2 RECEPTOR; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ALLOGRAFT; ANEMIA; ARTICLE; AUTOPSY; CAUDATE NUCLEUS; CELL THERAPY; CORPUS STRIATUM; DISEASE MODEL; DISSECTION; DRUG WITHDRAWAL; FETAL STRIATAL ALLOGRAFT; FETAL STRIATAL PRECURSOR TISSUE; FETAL STRIATAL TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUNTINGTON CHOREA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LATERAL GANGLIONIC EMINENCE TISSUE; MOTONEURON; MOTOR PERFORMANCE; NEPHROTOXICITY; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVE GRAFT; NERVE PROJECTION; NERVE TRANSPLANTATION; NERVOUS TISSUE; NEUROSURGERY; NONHUMAN; POSTOPERATIVE COMPLICATION; PUTAMEN; STEREOTAXIC SURGERY; TREATMENT DURATION; WHOLE GANGLIONIC EMINENCE TISSUE;

EID: 84855258568     PISSN: 16625145     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnint.2011.00078     Document Type: Article

References (78)

1. Bachoud-Levi, A., Bourdet, C., Brugieres, P., Nguyen, J. P., Grandmougin, T., Haddad, B., Jeny, R., Bartolomeo, P., Boisse, M. F., Barba, G. D., Degos, J. D., Ergis, A. M., Lefaucheur, J. P., Lisovoski, F., Pailhous, E., Rémy, P., Palfi, S., Defer, G. L., Cesaro, P., Hantraye, P., and Peschanski, M. (2000a). Safety and tolerability assessment of intrastriatal neural allografts in five patients with Hunt ington's disease. Exp. Neurol. 161, 194-202.
2. Bachoud-Levi, A. C., Remy, P., Nguyen, J. P., Brugieres, P., Lefaucheur, J. P., Bourdet, C., Baudic, S., Gaura, V., Maison, P., Haddad, B., Boissé, M. F., Grandmougin, T., Jény, R., Bartolomeo, P., Dalla Barba, G., Degos, J. D., Lisovoski, F., Ergis, A. M., Pailhous, E., Cesaro, P., Hantraye, P., and Peschanski, M. (2000b). Motor and cognitive improvements inpatientswithHuntington'sdisease after neural transplantation. Lancet 356,1975-1979.
3. Bachoud-Levi, A. C., Gaura, V., Brugieres, P., Lefaucheur, J. P., Boisse, M. F., Maison, P., Baudic, S., Ribeiro, M. J., Bourdet, C., Remy, P., Cesaro, P., Hantraye, P., and Peschanski, M. (2006). Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol. 5, 303-309.
4. Barker, R. A., and Swain, R. (2010). Neural transplantation for the treatment of Huntington's Disease. Eur. Neurol. Rev. 5, 41-45.
5. Barker, R. A., and Widner, H. (2004). Immune problems in central nervous system cell therapy. NeuroRx 1, 472-481.
6. Brasted, P. J., Watts, C., Torres, E. M., Robbins, T. W., and Dunnett, S. B. (1999). Behaviouralrecoveryfollowing striatal transplantation: effects of postoperative training and Pzone volume. Exp. Brain Res. 128, 535-538.
7. Brasted, P. J., Watts, C., Torres, E. M., Robbins, T. W., and Dunnett, S. B. (2000). Behavioral recovery after transplantation into a rat model of Huntington's disease: dependence on anatomical connectivity and extensive postoperative training. Behav. Neurosci. 114, 431-436.
8. Brundin, P., Barker, R. A., and Parmar, M. (2010). Neural grafting in Parkinson's disease problems and possibilities. Prog. Brain Res. 184, 265-294.
9. Brundin, P., Fricker, R. A., and Nakao, N. (1996). Paucity of P-zones in striatal grafts prohibit commencement of clinical trials in Huntington's disease. Neuroscience 71, 895-897.
10. Campbell, K., Kalen, P., Wictorin, K., Lundberg, C., Mandel, R. J., and Bjorklund, A. (1993). Characterization of GABA release from intrastriatal striatal transplants: dependence on host-derived afferents. Neuroscience 53, 403-415.
11. Capetian, P., Knoth, R., Maciaczyk, J., Pantazis, G., Ditter, M., Bokla, L., Landwehrmeyer, G. B., Volk, B., and Nikkhah, G. (2009). Histological findings on fetal striatal grafts in a Huntington's disease patient early after transplantation. Neuroscience 160,661-675.
12. Cicchetti, F., Saporta, S., Hauser, R. A., Parent, M., Saint-Pierre, M., Sanberg, P. R., Li, X. J., Parker, J. R., Chu, Y., Mufson, E. J., Kordower, J. H., and Freeman, T. B. (2009). Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 106, 12483-12488.
13. Cicchetti, F., Soulet, D., and Freeman, T. B. (2011). Neuronal degeneration in striataltransplantsandHuntington's disease: potential mechanisms and clinical implications. Brain 134(Pt 3),641-652.
14. Clarke, D. J., and Dunnett, S. B. (1993). Synaptic relationships between cortical and dopaminergic inputs and intrinsic GABAergic systems within intrastriatal striatal grafts. J. Chem. Neuroanat. 6, 147-158.
15. Clarke, D. J., Dunnett, S. B., Isacson, O., Sirinathsinghji, D. J., and Bjorklund, A. (1988). Striatal grafts in rats with unilateral neostriatal lesions I. Ultrastructural evidence of afferent synaptic inputs from the host nigrostriatal pathway. Neuroscience 24,791-801.
16. Coyle, J. T., and Schwarcz, R. (1976). Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263, 244-246.
17. DiFiglia, M. (1990). Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13, 286-289.
18. Dunnett, S. B. (1999). Striatal reconstruction by striatal grafts. J. Neural Transm. Suppl. 55, 115-129.
19. Dunnett, S. B., Carter, R. J., Watts, C., Torres, E. M., Mahal, A., Mangiarini, L., Bates, G., and Morton, A. J. (1998). Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154, 31-40.
20. Dunnett, S. B., Isacson, O., Sirinathsinghji, D. J., Clarke, D. J., and Bjorklund, A. (1988). Striatal grafts in rats with unilateral neostriatal lesions III. Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching. Neuroscience 24, 813-820.
21. Dunnett, S. B., and Rosser, A. E. (2007). Stem cell transplantation for Huntington's disease. Exp. Neurol. 203, 279-292.
22. Ferrante, R. J., Kowall, N. W., Cipolloni, P. B., Storey, E., and Beal, M. F. (1993). Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemicalcharacterization. Exp.Neurol. 119, 46-71.
23. Fink, J. S., Schumacher, J. M., Ellias, S. L., Palmer, E. P., Saint-Hilaire, M., Shannon, K., Penn, R., Starr, P., VanHorne, C., Kott, H. S., Dempsey, P. K., Fischman, A. J., Raineri, R., Manhart, C., Dinsmore, J., and Isacson, O. (2000). Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant. 9, 273-278.
24. Freeman, T. B., Cicchetti, F., BachoudLevi, A. C., and Dunnett, S. B. (2011). Technical factors that influence neural transplant safety in Huntington's disease. Exp. Neurol. 227,1-9.
25. Freeman, T. B., Cicchetti, F., Hauser, R. A., Deacon, T. W., Li, X. J., Hersch, S. M., Nauert, G. M., Sanberg, P. R., Kordower, J. H., Saporta, S., and Isacson, O.(2000).Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc. Natl. Acad. Sci. U.S.A. 97, 13877-13882.
26. Freeman, T. B., Sanberg, P. R., and Isacson, O. (1995). Development of the human striatum: implications for fetal striatal transplantation in the treatment of Huntington's disease. Cell Transplant. 4, 539-545.
27. Furtado, S., Sossi, V., Hauser, R. A., Samii, A., Schulzer, M., Murphy, C. B., Freeman, T. B., and Stoessl, A. J. (2005). Positron emission tomography after fetal transplantation in Huntington's disease. Ann. Neurol. 58,331-337.
28. Gallina, P., Paganini, M., Lombardini, L., Mascalchi, M., Porfirio, B., Gadda, D., Marini, M., Pinzani, P., Salvianti, F., Crescioli, C., Bucciantini, S., Mechi, C., Sarchielli, E., Romoli, A. M., Bertini, E., Urbani, S., Bartolozzi, B., De Cristofaro, M. T., Piacentini, S., Saccardi, R., Pupi, A., Vannelli, G. B., and Di Lorenzo, N. (2010). Human striatal neuroblasts develop and build a striatallike structure into the brain of Huntington's disease patients after transplantation. Exp. Neurol. 222, 30-41.
29. Gallina, P., Paganini, M., Lombardini, L., Saccardi, R., Marini, M., De Cristofaro, M. T., Pinzani, P., Salvianti, F., Crescioli, C., Di Rita, A., Bucciantini, S., Mechi, C., Sarchielli, E., Moretti, M., Piacentini, S., Gritti, G., Bosi, A., Sorbi, S., Orlandini, G., Vannelli, G. B., and Di Lorenzo, N (2008). Development of human striatal anlagen after transplantation in a patient with Huntington's disease. Exp. Neurol. 213, 241-244.
30. Gaura, V., Bachoud-Levi, A. C., Ribeiro, M. J., Nguyen, J. P., Frouin, V., Baudic, S., Brugieres, P., Mangin, J. F., Boisse, M. F., Palfi, S., Cesaro, P., Samson, Y., Hantraye, P., Peschanski, M., and Remy, P. (2004). Striatalneuralgraftingimprovescortical metabolism in Huntington's disease patients. Brain 127(Pt 1), 65-72.
31. Goodman, A. O., and Barker, R. A. (2010). How vital is sleep in Huntington's disease? J. Neurol. 257, 882-897.
32. Goodman, A. O., Murgatroyd, P. R., Medina-Gomez, G., Wood, N. I., Finer, N., Vidal-Puig, A. J., Morton, A. J., and Barker, R. A. (2008). The metabolic profile of early Huntington's disease a combined human and transgenic mouse study. Exp. Neurol. 210, 691-698.
33. Goodman, A. O., Rogers, L., Pilsworth, S., McAllister, C. J., Shneerson, J. M., Morton, A. J., and Barker, R. A. (2011). Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr. Neurol. Neurosci. Rep. 11, 821-827.
34. Graybiel, A. M., Liu, F. C., and Dunnett, S. B. (1989). Intrastriatal grafts derivedfromfetalstriatalprimordia. I. Phenotypy and modular organization. J. Neurosci. 9, 3250-3271.
35. Hauser, R. A., Furtado, S., Cimino, C. R., Delgado, H., Eichler, S., Schwartz, S., Scott, D., Nauert, G. M., Soety, E., Sossi, V., Holt, D. A., Sanberg, P. R., Stoessl, A. J., and Freeman, T. B. (2002). Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58, 687-695.
36. Ho, A. K., Gilbert, A. S., Mason, S. L., Goodman, A. O., and Barker, R. A. (2009). Health-related quality of life in Huntington's disease: which factors matter most? Mov. Disord. 24, 574-578.
37. Huntington Study Group. (2001). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57, 397-404.
38. Huntington Study Group TRENDHD Investigators. (2008). Randomized controlled trial of ethyleicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch. Neurol. 65, 1582-1589.
39. Isacson, O., Brundin, P., Kelly, P. A., Gage, F. H., and Bjorklund, A. (1984). Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature 311, 458-460.
40. Keene, C. D., Chang, R. C., Leverenz, J. B., Kopyov, O., Perlman, S., Hevner, R. F., Born, D. E., Bird, T. D., and Montine, T. J. (2009). A patient with Huntington's disease and longsurviving fetal neural transplants that developed mass lesions. Acta Neuropathol. 117, 329-338.
41. Keene, C. D., Sonnen, J. A., Swanson, P. D., Kopyov, O., Leverenz, J. B., Bird, T. D., and Montine, T. J. (2007). Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 68, 2093-2098.
42. Kendall, A. L., Rayment, F. D., Torres, E. M., Baker, H. F., Ridley, R. M., and Dunnett, S. B. (1998). Functional integration of striatal allografts in a primate model of Huntington's disease. Nat. Med. 4, 727-729.
43. Kopyov, O. V., Jacques, S., Lieberman, A., Duma, C. M., and Eagle, K. S. (1998). Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp. Neurol. 149, 97-108.
44. Kremer, B., Clark, C. M., Almqvist, E. W., Raymond, L. A., Graf, P., Jacova, C., Mezei, M., Hardy, M. A., Snow, B., Martin, W., and Hayden, M. R. (1999). Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53, 1000-1011.
45. Krystkowiak, P., Gaura, V., Labalette, M., Rialland, A., Remy, P., Peschanski, M., and Bachoud-Levi, A. C. (2007). Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington's disease. PLoS ONE 2, e166. doi:10.1371/journal.pone.0000166
46. Landwehrmeyer, G. B., Dubois, B., de Yebenes, J. G., Kremer, B., Gaus, W., Kraus, P. H., Przuntek, H., Dib, M., Doble, A., Fischer, W., Ludolph, A. C., and European Huntington's Disease Initiative Study Group. (2007). Riluzole in Huntington's disease: a 3-year,randomizedcontrolledstudy. Ann. Neurol. 62, 262-272.
47. Lazic, S. E., and Barker, R. A. (2004). Rapid decline in motor symptoms in HD neural transplant patients prior to surgery. Brain Res. Bull. 63,83-84.
48. Madrazo, I., Franco-Bourland, R. E., Castrejon, H., Cuevas, C., and Ostrosky-Solis, F. (1995). Fetal striatal homotransplantation for Huntington's disease: first two case reports. Neurol. Res. 17, 312-315.
49. Mestre, T., Ferreira, J., Coelho, M. M., Rosa, M., and Sampaio, C. (2009). Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst. Rev. CD006455.
50. Nakao, N., Grasbon-Frodl, E. M., Widner, H., and Brundin, P. (1996). DARPP-32-rich zones in grafts of lateral ganglionic eminence govern the extent of functional recovery in skilled paw reaching in an animal model of Huntington's disease. Neuroscience 74, 959-970.
51. Nithianantharajah, J., and Hannan, A. J. (2006). Enriched environments, experience-dependent plasticity and disordersof thenervoussystem. Nat. Rev. Neurosci. 7, 697-709.
52. Palfi, S., Conde, F., Riche, D., Brouillet, E., Dautry, C., Mittoux, V., Chibois, A., Peschanski, M., and Hantraye, P. (1998). Fetal striatal allografts reversecognitivedeficitsinaprimate model of Huntington disease. Nat. Med. 4, 963-966.
53. Peschanski, M., Cesaro, P., and Hantraye, P. (1995). Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 68, 273-285.
54. Peyser, C. E., Folstein, M., Chase, G. A., Starkstein, S., Brandt, J., Cockrell, J. R., Bylsma, F., Coyle, J. T., McHugh, P. R., and Folstein, S. E. (1995). Trial of d-alpha-tocopherol in Huntington's disease. Am. J. Psychiatry 152, 1771-1775.
55. Philpott, L. M., Kopyov, O. V., Lee, A. J., Jacques, S., Duma, C. M., Caine, S., Yang, M., and Eagle, K. S. (1997). Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant. 6, 203-212.
56. Politis, M., Wu, K., Loane, C., Quinn, N. P., Brooks, D. J., Rehncrona, S., Bjorklund, A., Lindvall, O., and Piccini, P. (2010). Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2, 38ra46.
57. Quinn, N., Brown, R., Craufurd, D., Goldman, S., Hodges, J., Kieburtz, K., Lindvall, O., MacMillan, J., and Roos, R. (1996). Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov. Disord. 11, 143-150.
58. Ranen, N. G., Peyser, C. E., Coyle, J. T., Bylsma, F. W., Sherr, M., Day, L., Folstein, M. F., Brandt, J., Ross, C. A., and Folstein, S. E. (1996). A controlled trial of idebenone in Huntington's disease. Mov. Disord. 11,549-554.
59. Reading, P. J., and Dunnett, S. B. (1995). Embryonic striatal grafts reverse the disinhibitory effects of ibotenic acid lesions of the ventral striatum. Exp. Brain Res. 105, 76-86.
60. Reuter, I., Tai, Y. F., Pavese, N., Chaudhuri, K. R., Mason, S., Polkey, C. E., Clough, C., Brooks, D. J., Barker, R. A., and Piccini, P. (2008). Longterm clinical and positron emission tomographyoutcomeof fetalstriatal transplantation in Huntington's disease. J. Neurol. Neurosurg. Psychiatr. 79,948-951.
61. Ross, C. A., and Tabrizi, S. J. (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98.
62. Rosser, A. E., Barker, R. A., Harrower, T., Watts, C., Farrington, M., Ho, A. K., Burnstein, R. M., Menon, D. K., Gillard, J. H., Pickard, J., Dunnett, S. B., and NEST-UK. (2002). Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J. Neurol. Neurosurg. Psychiatr. 73, 678-685.
63. Shoulson, I., Odoroff, C., Oakes, D., Behr, J., Goldblatt, D., Caine, E., Kennedy, J., Miller, C., Bamford, K., Rubin, A., Plumb, S., and Kurlan, R. (1989). A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol. 25, 252-259.
64. Sramka, M., Rattaj, M., Molina, H., Vojtassak, J., Belan, V., and Ruzicky, E. (1992). Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. Stereotact. Funct. Neurosurg. 58, 79-83.
65. Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., Borowsky, B., Tobin, A. J., Rosas, H. D., Johnson, H., Reilmann, R., Landwehrmeyer, B., Stout, J. C., and TRACK-HD investigators. (2009). Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 8, 791-801.
66. Tabrizi, S. J., Scahill, R. I., Durr, A., Roos, R. A., Leavitt, B. R., Jones, R., Landwehrmeyer, G. B., Fox, N. C., Johnson, H., Hicks, S. L., Kennard, C., Craufurd, D., Frost, C., Langbehn, D. R., Reilmann, R., Stout, J. C., and TRACK-HD Investigators. (2011). Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 10,31-42.
67. The Huntington's Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
68. Thu, D. C., Oorschot, D. E., Tippett, L. J., Nana, A. L., Hogg, V. M., Synek, B. J., Luthi-Carter, R., Waldvogel, H. J., and Faull, R. L. (2010). Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 133(Pt 4),1094-1110.
69. Tippett, L. J., Waldvogel, H. J., Thomas, S. J., Hogg, V. M., van Roon-Mom, W., Synek, B. J., Graybiel, A. M., and Faull, R. L. (2007). Striosomes and mood dysfunction in Huntington's disease. Brain 130(Pt 1), 206-221.
70. van Dellen, A., Blakemore, C., Deacon, R., York, D., and Hannan, A. J. (2000). Delaying the onset of Huntington's in mice. Nature 404, 721-722.
71. van Dellen, A., Cordery, P. M., Spires, T. L., Blakemore, C., and Hannan, A. J. (2008). Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neurosci. 9, 34. doi:10.1186/1471-2202-9-34
72. Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S., Vanhees, L., Van Leemputte, M., Hespel, P., and Dom, R.(2003).Creatinesupplementation in Huntington's disease: a placebocontrolled pilot trial. Neurology 61, 925-930.
73. Watts, C., Brasted, P. J., and Dunnett, S.B.(2000a).Embryonicdonor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease. Exp. Neurol. 163,85-97.
74. Watts, C., McNamara, I. R., and Dunnett, S. B. (2000b). Volume and differentiation of striatal grafts in rats: relationship to the number of cells implanted. Cell Transplant. 9, 65-72.
75. Watts, R. L., Mandir, A. S., and Bakay, R. A. (1995). Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTPinduced parkinsonian macaques: behavioral and anatomical assessment. Cell Transplant. 4, 27-38.
76. Watts, R. L., Subramanian, T., Freeman, A., Goetz, C. G., Penn, R. D., Stebbins, G. T., Kordower, J. H., and Bakay, R. A. (1997). Effect of stereotaxic intrastriatal cografts of autologous adrenal medulla and peripheral nerve in Parkinson's disease: two-year follow-up study. Exp. Neurol. 147, 510-517.
77. Wictorin, K. (1992). Anatomy and connectivity of intrastriatal striatal transplants. Prog. Neurobiol. 38, 611-639.
78. Wood, N. I., Goodman, A. O., van der Burg, J. M., Gazeau, V., Brundin, P., Bjorkqvist, M., Petersen, A., Tabrizi, S. J., Barker, R. A., and Morton, A. J. (2008). Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Res. Bull. 76, 70-79.